ArticleWorld journal of surgical oncology2026
LncRNA FRMD6-AS2 inhibits the malignant progression of bladder cancer by targeting miR-1260a.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ferroptosis-autophagy crosstalk in bladder cancer: mechanisms and therapeutic implications.Molecular cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder cancer (BC) ranks as the most prevalent malignant neoplasm affecting the urinary system. However, its clinical prevention and treatment continue to face significant challenges. This research aims to investigate the biological roles and regulatory mechanisms of FRMD6-AS2 in BC.
methodsTissue samples were collected from 132 BC patients, along with their matched adjacent normal tissues. Quantitative reverse transcription polymerase chain reaction was employed to determine FRMD6-AS2 and miR-1260a expression, and their correlation was assessed using Pearson correlation analysis. The link between FRMD6-AS2 and patient prognosis was analyzed via Kaplan-Meier and Cox regression analyses to identify independent prognostic factors. Cell proliferation, migration, invasion, and apoptosis were determined by employing the cell counting kit-8, Transwell, and Annexin V-fluorescein isothiocyanate/ propidium iodide assays. The direct binding interaction between FRMD6-AS2 and miR-1260a was verified by luciferase reporter and RNA immunoprecipitation assays.
resultsFRMD6-AS2 was lowly expressed in BC tissues and cells. Patients with low FRMD6-AS2 expression exhibited poorer overall survival, and it was identified as an independent prognostic factor. Overexpression of FRMD6-AS2 led to the inhibition of BC cell proliferation, migration, and invasion while promoting apoptosis. Mechanistically, FRMD6-AS2 negatively regulated miR-1260a expression. Furthermore, overexpression of miR-1260a partially reversed the suppressive impacts of FRMD6-AS2 on the malignant behaviors of BC cells.
conclusionFRMD6-AS2 exhibits reduced expression in BC and plays tumor-suppressive effects by sponging miR-1260a, suggesting its potential as a prognostic biomarker and therapeutic target for BC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.